Sugi Predict

Sugi Predict / Compounds / SCHEMBL2490637

SCHEMBL2490637

SCHEMBL2490637

Cn1nc(Nc2cc(-c3ccc(F)c(NC(=O)c4cc5ccccc5s4)c3)n[nH]c2=O)cc1C(C)(C)O

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 13/20 0.69
▸ FGR P09769 1/20 0.54
▸ SRC P12931 1/20 0.54
▸ TEC P42680 1/20 0.54
▸ BMX P51813 1/20 0.54
▸ HDAC1 Q13547 1/20 0.39
▸ TP53 P04637 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ MAPK9 P45984 2/20 0.37
▸ MAPK14 Q16539 2/20 0.37
▸ DHPS P49366 1/20 0.36
▸ SYK P43405 1/20 0.36
▸ TMIGD3 P0DMS9 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ STAT1 P42224 1/20 0.35
▸ CASP3 P42574 1/20 0.35
▸ SENP8 Q96LD8 1/20 0.35
▸ SENP7 Q9BQF6 1/20 0.35
▸ SENP6 Q9GZR1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2489386 0.93 BTK (0.70) BTKFGRSRCTECBMX
SCHEMBL2489542 0.89 BTK (0.73) BTKFGRSRCTECBMX
SCHEMBL2492952 0.89 BTK (0.55) BTKFGRSRCTECBMX
SCHEMBL2492464 0.87 BTK (0.70) BTKFGRSRCTECBMX
SCHEMBL9984587 0.87 BTK (0.71) BTKFGRSRCTECBMX
SCHEMBL2488913 0.84 BTK (0.69) BTKFGRSRCTECBMX
SCHEMBL2492835 0.84 BTK (0.67) BTKFGRSRCTECBMX
SCHEMBL2489592 0.83 BTK (0.69) BTKFGRSRCTECBMX
SCHEMBL9984366 0.83 BTK (0.64) BTKFGRSRCTECBMX
SCHEMBL2490588 0.83 BTK (0.66) BTKFGRSRCTECBMX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598174-B2 Pyridazinones, method of making, and method of use thereof GENETECH, INC. (US) 2013-12-03 — — US claimed
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF Gilead Connecticut INc. (US) 2011-12-08 — — US claimed
EP-2365970-B1 PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS GILEAD CONNECTICUT INC (US) 2018-03-21 — — EP disclosed
EP-2365970-B1 PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS GILEAD CONNECTICUT INC (US) 2018-03-21 — — EP disclosed
US-8598174-B2 Pyridazinones, method of making, and method of use thereof GENETECH, INC. (US) 2013-12-03 — — US disclosed
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF Gilead Connecticut INc. (US) 2011-12-08 — — US disclosed
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF Gilead Connecticut INc. (US) 2011-12-08 — — US disclosed
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF Gilead Connecticut INc. (US) 2011-12-08 — — US disclosed
EP-2365970-A1 Pyridazinones and their use as btk inhibitors CGI Pharmaceuticals, Inc. (US) 2011-09-21 — — EP disclosed
WO-2010056875-A1 PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2010-05-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF BTK, SYK, LCK BTK 1/4885FGR 1105/4885SRC 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.